Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Pharmaust Limited (NUZ) Share Price & Analysis

28 Followers

NUZ Stock Chart & Stats

A$0.06A$0.00(1.75%)
At close: 4:00 PM GMT+11
AU$0.06AU$0.07AU$0.08AU$0.09Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.06 - AUD 0.06
52-Week Range
AUD 0.05 - AUD 0.12
Previous Close
AUD 0.06
Volume
N/A
Average Volume (3M)
602.35K
Market Cap
AUD 48.76M
Enterprise Value
AUD 36.12M
Total Cash (Recent Filing)
AUD 12.71M
Total Debt (Recent Filing)
AUD 3.31M
Price to Earnings (P/E)
―
Beta
0.46
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Capitalization

The sharp increase in equity provides a larger capitalization cushion than the company had in 2025 and may improve its ability to support development activities. Although funding risk remains, stronger capitalization can provide greater resilience while management works toward commercial progress.

Narrower Annual Loss

The reduction in annual loss indicates some improvement in the company’s financial trajectory after the severe deterioration seen in 2025. If sustained, lower losses could extend funding capacity and reduce the cash required to advance pharmaceutical and animal-health programs.

Focused Healthcare Strategy

A focus on pharmaceutical development, drug repurposing, and veterinary applications gives Pharmaust a defined strategic base rather than an unrelated collection of activities. Repurposing and animal-health programs could support focused commercialization efforts if development initiatives achieve durable adoption.

Bears Say

Revenue Has Fallen To Zero

The absence of reported revenue for three consecutive years shows that the company has not yet established a functioning commercial revenue base. This weakens visibility into future self-funded growth and leaves results dependent on successfully converting development activities into sales.

Persistent Unprofitability

Large recurring losses and frequently negative gross profit point to an unfavorable operating structure and limited evidence of operating leverage. Even with the 2026 improvement, continued unprofitability can consume capital, constrain investment choices, and delay the path toward sustainable earnings.

Heavy Cash Burn And Renewed Debt

Sustained negative operating and free cash flow means the business is not currently funding itself through operations. The scale of recent cash burn, combined with renewed borrowing, increases reliance on external capital and reduces financial flexibility if commercialization takes longer than expected.

Pharmaust Limited News

NUZ FAQ

What was Pharmaust Limited’s price range in the past 12 months?
Pharmaust Limited lowest share price was AU$0.05 and its highest was AU$0.12 in the past 12 months.
What is Pharmaust Limited’s market cap?
Pharmaust Limited’s market cap is AU$48.76M.
When is Pharmaust Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaust Limited’s earnings last quarter?
Pharmaust Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.007 earnings per share for the quarter.
Is Pharmaust Limited overvalued?
According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued.
Does Pharmaust Limited pay dividends?
Pharmaust Limited does not currently pay dividends.
What is Pharmaust Limited’s EPS estimate?
Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaust Limited have?
Pharmaust Limited has 855,368,100 shares outstanding.
What happened to Pharmaust Limited’s price movement after its last earnings report?
Pharmaust Limited reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Pharmaust Limited?
Currently, no hedge funds are holding shares in AU:NUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology